Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: elranatamab, imc-gp100, talquetamab +13 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | PubMed did not answer (PubMed: HTTP 500) | 0.00 |
| pathways Reactome | 13 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 17065
Sealed predictions
- CD3G in dopamine neurons, braak-0.12 (p 0.750) → -0.23 (p 0.555)receipt 17072
Swarm cases
receipt 17072: CD3G in dopamine neurons, braak
- power
- full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.555, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.544, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.09, sign flips 4; without severely affected donors -0.04 (p 0.867, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD3G in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts